Caribou Biosciences, Inc. (CRBU)
0.4487
+0.04
(+8.83%)
USD |
NASDAQ |
Nov 06, 16:00
0.4423
-0.01
(-1.43%)
After-Hours: 20:00
Caribou Biosciences Research and Development Expense (Annual) : 109.44M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 109.44M |
| December 31, 2024 | 130.15M |
| December 31, 2023 | 112.08M |
| December 31, 2022 | 82.23M |
| Date | Value |
|---|---|
| December 31, 2021 | 52.26M |
| December 31, 2020 | 34.42M |
| December 31, 2019 | 23.64M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Anavex Life Sciences Corp. | 37.59M |
| Vaxcyte, Inc. | 794.31M |
| Foghorn Therapeutics, Inc. | 82.13M |
| Bolt Biotherapeutics, Inc. | 27.04M |
| Connect Biopharma Holdings Ltd. | 37.80M |